Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | NPY4R | P50391 | 10/20 | 0.37 |
| ▸ | NPY1R | P25929 | 7/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.37 |
| ▸ | NPY2R | P49146 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | NMT2 | O60551 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589718 | 0.86 | GRIA1 (0.38) | GRIA1SIRT6SIRT1NPY4RNPY1R | |
| SCHEMBL16589724 | 0.85 | SIRT6 (0.55) | GRIA1SIRT6SIRT1MMP1MMP3 | |
| SCHEMBL1724846 | 0.83 | FOLH1 (0.40) | GRIA1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4552682 | 0.83 | FOLH1 (0.40) | GRIA1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16263587 | 0.82 | SIRT6 (0.42) | SIRT6SIRT1NPY4RNPY1RNPY5R | |
| SCHEMBL18464241 | 0.81 | NPY4R (0.42) | GRIA1NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16589745 | 0.81 | GRIA1 (0.43) | GRIA1SIRT6SIRT1MMP1MMP3 | |
| SCHEMBL16260140 | 0.80 | SIRT6 (0.40) | SIRT6SIRT1NPY4RNPY1RNPY5R | |
| SCHEMBL29447204 | 0.79 | NPY4R (0.50) | SIRT6SIRT1NPY4RNPY1RNPY5R | |
| SCHEMBL16589748 | 0.78 | CCKBR (0.45) | GRIA1SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ABCB1, CYP2D6, LDHA | GRIA1 3272/4885SIRT6 1290/4885SIRT1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.